Impact BioMedical amends merger deal with Dr Ashleys; extends deadline to July 1, 2026

IMPACT BIOMEDICAL INC.

Amendment adds 53,000 and 75,000 PubCo ordinary shares to be issued to DSS, Inc. at closing.
Total Company Share Consideration set at 169,560,000 PubCo shares (94.20% of post-closing outstanding).
Termination date extended from March 31, 2026 to July 1, 2026, with mutual extension option.
Impact must seek board approval to co-sign loan agreements requested by PubCo or Dr Ashleys before effective time.
Supporting stockholders now hold 92,980,843 Impact shares (88.87% fully diluted); holdings of DSS, Inc. and DSS BioHealth updated.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

IMPACT BIOMEDICAL INC. amended Amendment No. 1 to the Merger and Share Exchange Agreement with Dr Ashleys Limited, Dr Ashleys Nevada Sub, Inc., Dr Ashleys Bio Labs Limited, Kanans Visvanats (effective 2026-02-27).

Action: amendment
Agreement: merger
Counterparty: Dr Ashleys Limited, Dr Ashleys Nevada Sub, Inc., Dr Ashleys Bio Labs Limited, Kanans Visvanats
Effective: 2026-02-27

Exact text from the filing

On February 27, 2026, the parties entered into Amendment No. 1 to the Merger and Share Exchange Agreement (the “Amendment to the Original Merger and Share Exchange Agreement” and, together with the Original Merger and Share Exchange Agreement, the “Merger and Share Exchange Agreement”).

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

IMPACT BIOMEDICAL INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-008879

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.